PURPOSE: Based upon promising preclinical and phase 1 trial results, combined flavopiridol and cisplatin therapy was evaluated in patients with ovarian and primary peritoneal cancers. METHODS: A two cohort phase 2 trial of cisplatin (60 mg/m2 IV) immediately followed by flavopiridol (100 mg/m2 IV, 24 h infusion; 21 day cycles) was undertaken in patients with recurrent platin-sensitive or platin-resistant disease (progression>vs. ≤6 months following prior platin-based therapy). Measurable disease (RECIST)--or evaluable disease plus CA125>2X post-treatment nadir--and ECOG performance≤2 were required. RESULTS: Forty-five patients were enrolled between December 23, 2004 and February 25, 2010: 40 platin-resistant (Group 1), and 5 platin-sensitive (Group 2). In Group 1, the median number of treatment cycles was 3 (range 2-12). Only 10% of patients incurred grade 4 toxicities, but grade 3 toxicities were common (65%): neutropenia (17.5%); nausea (12.5%); vomiting, fatigue, thrombosis, anemia (10% each). Seven patients (17.5%) achieved a confirmed response (1 CR, 6 PR; median duration 118 days); ten additional patients (25%) attained maintained stable disease. Median time to progression was 4.3 months; overall survival was 16.1 months. Pilot translational studies assessed ascites flavopiridol level; surrogate marker studies were uninformative. In Group 2, although 4 of 5 patients responded (2 confirmed PRs with median time to progression, 10.8 months and median overall survival 20.6 months) the cohort was closed due to poor accrual. CONCLUSIONS: The assessed flavopiridol and cisplatin regimen displayed clinical activity in platin resistant and sensitive ovarian/primary peritoneal cancers, meriting further study.
PURPOSE: Based upon promising preclinical and phase 1 trial results, combined flavopiridol and cisplatin therapy was evaluated in patients with ovarian and primary peritoneal cancers. METHODS: A two cohort phase 2 trial of cisplatin (60 mg/m2 IV) immediately followed by flavopiridol (100 mg/m2 IV, 24 h infusion; 21 day cycles) was undertaken in patients with recurrent platin-sensitive or platin-resistant disease (progression>vs. ≤6 months following prior platin-based therapy). Measurable disease (RECIST)--or evaluable disease plus CA125>2X post-treatment nadir--and ECOG performance≤2 were required. RESULTS: Forty-five patients were enrolled between December 23, 2004 and February 25, 2010: 40 platin-resistant (Group 1), and 5 platin-sensitive (Group 2). In Group 1, the median number of treatment cycles was 3 (range 2-12). Only 10% of patients incurred grade 4 toxicities, but grade 3 toxicities were common (65%): neutropenia (17.5%); nausea (12.5%); vomiting, fatigue, thrombosis, anemia (10% each). Seven patients (17.5%) achieved a confirmed response (1 CR, 6 PR; median duration 118 days); ten additional patients (25%) attained maintained stable disease. Median time to progression was 4.3 months; overall survival was 16.1 months. Pilot translational studies assessed ascitesflavopiridol level; surrogate marker studies were uninformative. In Group 2, although 4 of 5 patients responded (2 confirmed PRs with median time to progression, 10.8 months and median overall survival 20.6 months) the cohort was closed due to poor accrual. CONCLUSIONS: The assessed flavopiridol and cisplatin regimen displayed clinical activity in platin resistant and sensitive ovarian/primary peritoneal cancers, meriting further study.
Authors: Keith C Bible; Janet L Lensing; Sacha A Nelson; Yean K Lee; Joel M Reid; Matthew M Ames; Crescent R Isham; Jill Piens; Stacie L Rubin; Joseph Rubin; Scott H Kaufmann; Pamela J Atherton; Jeffrey A Sloan; Michelle K Daiss; Alex A Adjei; Charles Erlichman Journal: Clin Cancer Res Date: 2005-08-15 Impact factor: 12.531
Authors: K C Bible; R H Bible; T J Kottke; P A Svingen; K Xu; Y P Pang; E Hajdu; S H Kaufmann Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: Michael V Seiden; Alan N Gordon; Diane C Bodurka; Ursula A Matulonis; Richard T Penson; Eddie Reed; Dave S Alberts; Garry Weems; Michael Cullen; William P McGuire Journal: Gynecol Oncol Date: 2005-11-02 Impact factor: 5.482
Authors: Koen De Geest; John A Blessing; Robert T Morris; S Diane Yamada; Bradley J Monk; Susan L Zweizig; Daniela Matei; Carolyn Y Muller; William E Richards Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Teddy S Nagaria; Julia L Williams; Charles Leduc; Jeremy A Squire; Peter A Greer; Waheed Sangrar Journal: Neoplasia Date: 2013-08 Impact factor: 5.715
Authors: Olivia Perwitasari; Xiuzhen Yan; Jason O'Donnell; Scott Johnson; Ralph A Tripp Journal: Assay Drug Dev Technol Date: 2015-07-20 Impact factor: 1.738